WHO Raises Alert Over Severe Lack of Weight-Loss Jabs

Fewer than one in 10 patients eligible to benefit from obesity jabs including Wegovy are able to get them, states the WHO as it releases its inaugural guidance on the medications.

Considering over a billion people worldwide now obese, it is calling for increased and just access to these injectable treatments.

Per forecasts, more than two billion could be obese by 2030 without intervention.

"Our new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are key barriers to universal availability to the treatments that can assist patients in reducing significant body mass, says the body.

GLP-1 Therapy Supply Crisis

Even under the present best projected case, the production of GLP-1 therapies could only cover approximately 100 million people – less than 10% of the global need, per the health organization.

The recommendation urges nations and manufacturers to widen availability, through approaches such as patent sharing.

The intellectual property rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.

The Way Obesity Jabs Operate

These medications mimick a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so users consume fewer calories.

Patients usually start to lose weight in the initial weeks of starting on the once-weekly jabs.

Evidence indicates people may see weight return within a year of stopping the treatment, because their typical appetite resume.

To be carrying excess weight elevates your risk for developing medical conditions, like diabetes, cardiovascular issues, stroke, and certain malignancies.

Excess weight concerns people in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.